JP2006521810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521810A5 JP2006521810A5 JP2006507201A JP2006507201A JP2006521810A5 JP 2006521810 A5 JP2006521810 A5 JP 2006521810A5 JP 2006507201 A JP2006507201 A JP 2006507201A JP 2006507201 A JP2006507201 A JP 2006507201A JP 2006521810 A5 JP2006521810 A5 JP 2006521810A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- mammal
- tissue cells
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 210000004027 cell Anatomy 0.000 claims 29
- 241000124008 Mammalia Species 0.000 claims 27
- 239000000523 sample Substances 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 7
- 239000013068 control sample Substances 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 201000004681 Psoriasis Diseases 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45402503P | 2003-03-11 | 2003-03-11 | |
| PCT/US2004/007862 WO2004081199A2 (en) | 2003-03-11 | 2004-03-10 | Novel compositions and methods for the treatment of immune related disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006521810A JP2006521810A (ja) | 2006-09-28 |
| JP2006521810A5 true JP2006521810A5 (enExample) | 2007-05-10 |
Family
ID=32990856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507201A Withdrawn JP2006521810A (ja) | 2003-03-11 | 2004-03-10 | 免疫関連疾患の治療のための新規組成物と方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070037741A1 (enExample) |
| EP (1) | EP1601693A2 (enExample) |
| JP (1) | JP2006521810A (enExample) |
| AU (1) | AU2004219603A1 (enExample) |
| CA (1) | CA2518552A1 (enExample) |
| WO (1) | WO2004081199A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005059242A1 (de) | 2005-12-12 | 2007-06-14 | Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten | Molekulare Marker für eine Tumordiagnose und -therapie |
| US8034782B2 (en) * | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2373690B1 (en) | 2008-12-08 | 2015-02-11 | Compugen Ltd. | Antibodies specific for tmem154 |
| WO2012035518A1 (en) | 2010-09-17 | 2012-03-22 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| US11136401B2 (en) | 2015-03-27 | 2021-10-05 | University Of Southern California | Car t-cell therapy directed to LHR for the treatment of solid tumors |
| WO2016160622A2 (en) * | 2015-03-27 | 2016-10-06 | University Of Southern California | Hla-g as a novel target for car t-cell immunotherapy |
| AU2016270474A1 (en) | 2015-06-04 | 2018-01-04 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
| JP2022520106A (ja) | 2019-02-15 | 2022-03-28 | ユニバーシティ オブ サザン カリフォルニア | Lym-1およびlym-2抗体組成物ならびに改善されたcar構築物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2110986T3 (es) * | 1991-08-12 | 1998-03-01 | Nestle Sa | Composicion alimenticia. |
| CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| AU6910800A (en) * | 1999-08-12 | 2001-03-13 | California Institute Of Technology | An animal model of polyglutamine toxicity, methods of use, and modulators of polyglutamine toxicity |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002019965A2 (en) * | 2000-09-07 | 2002-03-14 | Science & Technology Corporation @ Unm | Heat shock response and virus replication |
| WO2003004646A2 (en) * | 2001-04-04 | 2003-01-16 | Elan Corporation, Plc | Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors |
| EP1369482A1 (en) * | 2002-06-07 | 2003-12-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target genes for the diagnosis and treatment of cancer |
| EP2500438A3 (en) * | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
-
2004
- 2004-03-10 AU AU2004219603A patent/AU2004219603A1/en not_active Abandoned
- 2004-03-10 EP EP04719326A patent/EP1601693A2/en not_active Withdrawn
- 2004-03-10 JP JP2006507201A patent/JP2006521810A/ja not_active Withdrawn
- 2004-03-10 US US10/548,553 patent/US20070037741A1/en not_active Abandoned
- 2004-03-10 WO PCT/US2004/007862 patent/WO2004081199A2/en not_active Ceased
- 2004-03-10 CA CA002518552A patent/CA2518552A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010162016A5 (enExample) | ||
| CN105980407B (zh) | 单克隆抗tk1抗体 | |
| JP2006516094A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| CA2503125A1 (en) | Novel composition and methods for the treatment of immune related diseases | |
| JP2008301822A5 (enExample) | ||
| CA2479494A1 (en) | Compositions and methods associated with pro5725 and its use for the diagnosis of lung and colon tumor | |
| WO2015067768A1 (en) | High-affinity monoclonal anti-strep-tag antibody | |
| JP2006223304A5 (enExample) | ||
| JP2006521810A5 (enExample) | ||
| HK1221490A1 (zh) | 以生物樣品進行的針對igfbp7的具有改進的性能的測定 | |
| WO2016002189A1 (ja) | 抗プログルカゴン抗体 | |
| CN110545843A (zh) | 识别遗传变体的抗体 | |
| KR20210049894A (ko) | 항-인간 심근 트로포닌 i 재조합 항체 | |
| US20140243265A1 (en) | Antibodies to modified human igf-1/e peptides | |
| JP2006521082A5 (enExample) | ||
| US20230384326A1 (en) | Test method and test kit for adult still's disease | |
| JP2006518582A5 (enExample) | ||
| JP5821198B2 (ja) | 抗il28b抗体及びこれを用いたil28bの測定方法 | |
| JP2008515388A5 (enExample) | ||
| WO2021237534A1 (zh) | 抗新型冠状病毒的抗体、抗体组合、制备方法、包含其的检测试剂盒 | |
| JP2010029191A5 (enExample) | ||
| WO2021238854A1 (zh) | 抗SARS-CoV-2刺突蛋白的单克隆抗体及其制备方法和用途 | |
| CN117843774A (zh) | 一种莱茵衣藻nphp8蛋白的兔多克隆抗体及其制备方法和应用 | |
| JP2006515748A5 (enExample) |